20:12.04.12

B01AE07

211915-06-9

pradax

pradaxa

rendix

dabigatran etexilate mesilate

dabigatran

ethyl 3-[[[4-[[[(hexyloxyl)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1h-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino] propanoate (inn)

An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amino group of ethyl N-pyridin-2-yl-beta-alaninate. A prodrug for dabigatran, a thrombin inhibitor and anticoagulant which is used for the prevention of stroke and systemic embolism.

Dabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. FDA approved on October 19, 2010.

InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)

InChIKey=KSGXQBZTULBEEQ-UHFFFAOYSA-N

dabigatran etexilate

obo2:CHEBI_70746

dabigatran etexilate

CCCCCCOC(=O)N=C(N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=CC=CC=N3)N2C)C=C1

CCCCCCOC(=O)\\N=C(\\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1

ethyl N-[(2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alaninate

dabigatran etexilate

ethyl 3-(1-{2-[({4-[amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate

C34H41N7O5

CiteXplore:22803489

Drugs.com:http://www.drugs.com/cdi/dabigatran.html

Patent:WO2012077136

CiteXplore:22348256

Patent:US2011275824

CiteXplore:22669799

CiteXplore:22276081

CiteXplore:23476049

CASRN:211915-06-9

ChemSpider:4948999

CiteXplore:21542663

PDRhealth:http://www.pdrhealth.com/drugs/pradaxa

ChEBI:70746

CiteXplore:22431533

CiteXplore:22552763

KEGG DRUG:D07144

CiteXplore:22298812

PubChem Substance:99443249

CiteXplore:21859976

Wikipedia:http://en.wikipedia.org/wiki/Dabigatran

PharmGKB:PA165958369

CiteXplore:22422743

CiteXplore:21748501

PubChem Compound:6445226

CiteXplore:22252796

CiteXplore:21881389

National Drug Code Directory:21695-899-60

CiteXplore:22564134

CiteXplore:21429525

Reaxys:15496119

Patent:WO2007047608

ChEMBL:661520

CiteXplore:22488474

CiteXplore:22995531

HMDB:HMDB15641

CiteXplore:21265583

CiteXplore:22563715

CiteXplore:22536678

Patent:WO2012027543

RxList:http://www.rxlist.com/pradaxa-drug.htm

CiteXplore:22318514

Patent:WO2011061080

CiteXplore:22782539